ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing

References

• Rocks N, Paulissen G, El Hour M, Quesada F, Crahay C, Gueders M, Foidart JM, Noel A, Cataldo D. Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie 2008; 90:369-79; PMID:17920749; http://dx.doi.org/10.1016/j.biochi.2007.08.008
   PubMed Web of Science ®Google Scholar
• Saftig P, Reiss K. The “A Disintegrin And Metalloproteases” ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol 2011; 90:527-35; PMID:21194787; http://dx.doi.org/10.1016/j.ejcb.2010.11.005
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Mullooly M, O'Donovan N, Sukor S, Crown J, Pierce A, McGowan PM. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics 2011; 8:9-13; PMID:21906355; http://dx.doi.org/10.1186/1559-0275-8-9
   PubMedGoogle Scholar
• Blobel CP. ADAMs: key components in EGFR signalling and development. Nature Rev Cancer 2005; 6:32-43; PMID:15688065; http://dx.doi.org/10.1038/nrm1548
   PubMed Web of Science ®Google Scholar
• Duffy MJ, McKiernan E, O'Donovan N, McGowan P. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2007; 13:2335-43; PMID:17438092; http://dx.doi.org/10.1158/1078-0432.CCR-06-2092
   PubMed Web of Science ®Google Scholar
• Murphy G. The ADAMs: Signalling scissors in the tumor microenvironment. Nature Rev Cancer 2008; 8:929-41; PMID:19005493; http://dx.doi.org/10.1038/nrc2459.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 2006; 66(5):2520-26; PMID:16510567; http://dx.doi.org/10.1158/0008-5472.CAN-05-2520
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008; 68(15):6368-76; PMID:18676862; http://dx.doi.org/10.1158/0008-5472.CAN-07-6768
   PubMed Web of Science ®Google Scholar
• Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008; 27:5944-58; PMID:18836475; http://dx.doi.org/10.1038/onc.2008.272
   PubMed Web of Science ®Google Scholar
• Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235:267-85; PMID:20536569; http://dx.doi.org/10.1111/j.0105-2896.2010.00893.x
   PubMed Web of Science ®Google Scholar
• Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389-96; PMID:12714493; http://dx.doi.org/10.1182/blood-2003-01-0019
   PubMed Web of Science ®Google Scholar
• Hayday AC. γδT cells and the lymphoid stress-surveillance response. Immunity 2009; 31:184-96; PMID:19699170; http://dx.doi.org/10.1016/j.immuni.2009.08.006
   PubMed Web of Science ®Google Scholar
• Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, Steinle A, Ghia P, Stella S, Caligaris-Cappio F et al. Vδ1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res 2004; 64:9172-9; PMID:15604289; http://dx.doi.org/10.1158/0008-5472.CAN-04-2417
   PubMed Web of Science ®Google Scholar
• Poggi A, Catellani S, Garuti A, Pierri I, Gobbi M, Zocchi MR. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by ATRA acid or VPA. Leukemia 2009; 23:641-8; PMID:19151770; http://dx.doi.org/10.1038/leu.2008.354
   PubMed Web of Science ®Google Scholar
• Catellani S, Poggi A, Bruzzone A, Dadati P, Ravetti JL, Gobbi M, Zocchi MR. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas ex pressing UL-16-binding proteins. Blood 2007; 109:2078-85; PMID:16973957; http://dx.doi.org/10.1182/blood-2006-06-028985
   PubMed Web of Science ®Google Scholar
• Zocchi MR, Catellani S, Canevali P, Tavella S, Garuti A, Villaggio B, Zunino A, Gobbi M, Fraternali-Orcioni G, Kunkl A et al. High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D-ligands recognition in Hodgkin lymphomas. Blood 2012; 119:1479-89; PMID:22167753; http://dx.doi.org/10.1182/blood-2011-07-370841
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature 2002; 419:734-8; PMID:12384702; http://dx.doi.org/10.1038/nature01112
   PubMed Web of Science ®Google Scholar
• Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MIC-A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci USA 2008; 105:1285-90; PMID:18202175; http://dx.doi.org/10.1073/pnas.0711293105
   PubMed Web of Science ®Google Scholar
• Nückel H, Switala M, Sellmann L, Horn PA, Dürig J, Dührsen U, Küppers R, Grosse-Wilde H, Rebmann V. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia 2010; 24:1152-59; PMID:20428196; http://dx.doi.org/10.1038/leu.2010.74
   PubMed Web of Science ®Google Scholar
• Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, Lo Y, Baribaud F, Mikami I, Reguart N et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 2006; 10:39-50; PMID:16843264; http://dx.doi.org/10.1016/j.ccr.2006.05.024
   PubMed Web of Science ®Google Scholar
• Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metallo proteiase inhibitor. Cancer Res 2008; 68:7082-89; PMID:18757423; http://dx.doi.org/10.1158/0008-5472.CAN-08-0739
   Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Liu X, Caulder E, Hansbury M, Yang G, Wang Q, Lo Y, Zhou J, Yao W et al. Preclinical characterization of INCB7839, a potent and selective inhibitor of Erb ligand and HER2 receptor shedding: inhibition of ADAM10 and ADAM17 for the treatment of breast cancer. Breast Cancer Res Treat 2007; 106(Suppl1):S82.
   Google Scholar
• Moss ML, Stoeck A, Yan W, Dempsey PJ. ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol 2008; 9:2-8; PMID:18289051; http://dx.doi.org/10.2174/138920108783497613
   PubMed Web of Science ®Google Scholar
• Theocharis AD, Gialeli C, Bouris P, Giannopoulou E, Skandalis SS, Aletras AJ, Iozzo RV, Karamanos NK. Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer. FEBS J 2014; 281:5023-42; PMID:25333340; http://dx.doi.org/10.1111/febs.12927
   PubMed Web of Science ®Google Scholar
• Nuti E, Casalini F, Santamaria S, Fabbi M, Carbotti G, Ferrini S, Marinelli L, La Pietra V, Novellino E, Camodeca C et al. Selective Arylsulfonamide Inhibitors of ADAM-17:Hit Optimization and Activity in Ovarian Cancer Cell. Models J Med Chem 2013; 56:8089-103; PMID:24044434; http://dx.doi.org/10.1021/jm4011753
   PubMed Web of Science ®Google Scholar
• Nuti E, Casalini F, Avramova SI, Santamaria S, Fabbi M, Ferrini S, Marinelli L, La Pietra V, Limongelli V, Novellino E et al. Potent arylsulfonamide inhibitors of tumor necrosis factor-α converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models. J Med Chem 2010; 53:2622-35; PMID:20180536; http://dx.doi.org/10.1021/jm901868z
   PubMed Web of Science ®Google Scholar
• Poggi A, Zancolli M, Boero S, Catellani S, Musso A, Zocchi MR. Differential survival of γδT cells, αβT cells and NK cells upon engagement of NKG2D by NKG2DL-expressing leukemic cells. Int J Cancer 2011; 129:387-96; PMID:20853320; http://dx.doi.org/10.1002/ijc.25682
   PubMed Web of Science ®Google Scholar
• Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Fürst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int J Cancer 2013; 133:1557-67; PMID:23526433; http://dx.doi.org/10.1002/ijc.28174
   PubMed Web of Science ®Google Scholar
• Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102:1186-95; PMID:12714508; http://dx.doi.org/10.1182/blood-2002-12-3775
   PubMed Web of Science ®Google Scholar
• Gober Hj, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003; 197:163-68; PMID:12538656; http://dx.doi.org/10.1084/jem.20021500
   PubMed Web of Science ®Google Scholar
• Bonneville M, O'Brien RL, Born, WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010; 10:467-78; PMID:20539306; http://dx.doi.org/10.1038/nri2781
   PubMed Web of Science ®Google Scholar
• Kunzman V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of T cells by aminobiphosphonates and induction of anti-plasma cell activity in multiple myeloma. Blood 2000; 96:384-92; PMID:10887096.
   PubMed Web of Science ®Google Scholar
• Musso A, Catellani S, Canevali P, Tavella S, Venè R, Boero S, Pierri I, Gobbi M, Kunkl A, Ravetti JL et al. Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ2 T lymphocytes in non-Hodgkin lymphomas. Haematologica 2014; 99:131-9; PMID:24162786; http://dx.doi.org/10.3324/haematol.2013.097311
   PubMed Web of Science ®Google Scholar
• Nakayama S, Yokote T, Tsuji M, Akioka T, Miyoshi T, Hirata Y, Hiraoka N, Iwaki N, Takayama A, Nishiwaki U et al. Expression of tumour necrosis factor-α and its receptors in Hodgkin lymphoma. Br J Haematol 2014; 167:574-7; PMID:25039986; http://dx.doi.org/10.1111/bjh.13015
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Simhadri VL, von Strandmann EP, Ludwig A, Matthews V, Reiners KS, von Tresckow B, Saftig P, Rose-John S, Engert A et al. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro. Cancer Res. 2007; 67:332-8; PMID:17210715; http://dx.doi.org/10.1158/0008-5472.CAN-06-2470
   PubMed Web of Science ®Google Scholar